This metabolic-immunologic crosstalk, supported by the ADAR1–KYNU axis, could enhance tumor cell survival, resistance to immune clearance, and metastatic potential, especially in the immune-cold microenvironment characteristic of TNBC. The gene discussed is ADAR; the disease is neoplasm.